Universidad de Navarra
Organización
Alexandra Hospital
Atenas, GreciaPublicaciones en colaboración con investigadores/as de Alexandra Hospital (10)
2018
2016
-
Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma
Journal of Clinical Oncology, Vol. 34, Núm. 32, pp. 3921-3930
2015
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152
-
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Haematologica, Vol. 100, Núm. 10, pp. 1327-1333
-
Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma
Haematologica, Vol. 100, Núm. 2, pp. 63-67
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Haematologica, Vol. 100, Núm. 10, pp. 1334-1339
-
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 9, pp. 519-530
2012
-
Mortality after surgery in Europe: A 7 day cohort study
The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065
2009
-
Atherosclerosis in rheumatoid arthritis versus diabetes: A comparative study
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 29, Núm. 10, pp. 1702-1708
-
VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study
CLINICAL LYMPHOMA & MYELOMA